For most biotechs, the huge cost of a late-stage diabetes drug program is enough to shut down any discussion about pushing through alone to an approval. Intarcia, though, says it now has the money needed to do just that for new technology billed as a prospective game-changer for one of the world’s most prevalent diseases.

…read more

Source: Investors pump $200M into Intarcia’s PhIII for once-yearly diabetes therapy


0 No comments